Cost-effectiveness analysis, prevention of atopic dermatitis by oral application of bacterial lysate in newborns/small children

Peter Kiencke (), Kristina Viehmann and Reinhard Rychlik

The European Journal of Health Economics, 2013, vol. 14, issue 6, 995-1002

Abstract: Prophylactic treatment with bacterial lysate of infants with single heredity for atopy for 26 weeks in the 1st year of life is cost-effective at the age of 3 and 6 years, i.e. prophylactic use of bacterial lysate generated lower costs by leading to lower prevalence compared to placebo. Copyright Springer-Verlag Berlin Heidelberg 2013

Keywords: Cost-effectiveness; Atopic dermatitis; Newborns; Small children; Prophylactic treatment; Escherichia coli; Enterococus faecalis; Sterile bacterial lysate; Model; Decision tree; I10 (search for similar items in EconPapers)
Date: 2013
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1007/s10198-012-0448-x (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:14:y:2013:i:6:p:995-1002

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-012-0448-x

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().